Advertisement

Vaccine Design pp 167-173 | Cite as

Interleukin 1 and Its Synthetic Peptide 163–171 as Vaccine Adjuvants

  • Aldo Tagliabue
  • Diana Boraschi
Chapter
Part of the NATO ASI Series book series (NSSA, volume 293)

Abstract

Interleukin 1 (IL-1) is a family of cytokines of key importance in the mechanisms of host defense, being involved in the onset and development of both immune and inflammatory reactions (Dinarello, 1991; Boraschi and Tagliabue, 1989). The IL-1 family includes IL-1α and IL-1γ, which have similar structures and overlapping biological activities, and IL-1ra, which is a pure receptor antagonist, able to occupy the activating IL-1 receptor (IL-1RI) without exerting any agonistic effect. IL-1 binds to two types of receptors on the cell surface. IL-1RI (CDw121a) is an 80 kDa monomeric transmembrane glycoprotein of the immunoglobulin superfamily which is responsible for initiating the cell activation mechanism upon IL-1 binding. Both agonist IL-1α and IL-1β and antagonist IL-1ra bind equally well to IL-1RI. Conversely, IL-1RII (CDw121b) is a 68 kDa receptor very similar to IL-1RI in its extracellular domain, but apparently unable to initiate cell activation. The extracellular IL-1 binding domain of IL-1RII can be naturally released from the cell surface and can capture IL-1β (Fig. 1).

Keywords

Vaccine Adjuvant Muramyl Dipeptide Active Specific Immunotherapy Specific Antibody Titer Human Ferritin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Beckers, W., Villa, L., Gonfioni, S., Castagnoli, L., Newton, S.M.C., Cesareni, G. and Ghiara, P., 1993, Increasing the immunogenicity of protein antigens through the genetic insertion of VQGEESNDK sequence of human IL-1γ into their sequence, J. Immunol., 151: 1757.PubMedGoogle Scholar
  2. Boraschi, D. and Tagliabue, A., 1989, Structure-function relationship of interleukin-1 giving new insights for its therapeutic potential. Biotherapy, 1: 377.PubMedCrossRefGoogle Scholar
  3. Boraschi, D., Nencioni, L., Villa, L., Censini, S., Bossù, P., Ghiara, P., Presentini, R., Perin, F., Frasca, D., Doria, G., Forni, G., Musso, T., Giovarelli, M., Ghezzi, P., Bertini, R., Besedovsky, H.O., del Rey, A., Sipe, J.D., Antoni, G., Silvestri S. and Tagliabue, A., 1988, In vivo stimulation and restoration of the immune response by the noninflammatory fragment 163–171 of human interleukin 1γ, J. Exp.Med., 168: 675.PubMedCrossRefGoogle Scholar
  4. Boraschi, D., Bossù, P., Ruggiero, P., Tagliabue, A., Bertini, R., Macchia, G., Gasbarro, C., Pellegrini, L., Melillo, G., Ulisse, E., Visconti, U., Bizzarri, C., Del Grosso, E., Mackay, A.R., Frascotti, G., Frigerio, F., Grifantini, R. and Grandi, G., 1995, Mapping of receptor binding sites on IL-lγ by reconstruction of IL-1ra-like domains, J.Immunol., 155: 4719.PubMedGoogle Scholar
  5. Dinarello, C.A., 1991, Interleukin-1 and interleukin-1 antagonism, Blood, 77: 1627.PubMedGoogle Scholar
  6. Forni, G., Musso, T., Jemma, C., Boraschi, D., Tagliabue, A. and Giovarelli, M., 1989, Lymphokine activated tumor inhibition (LATI) in mice. Ability of a nonapeptide of the human IL-1β to recruit anti-tumor reactivity in recipient mice, J.Immunol., 142: 712.PubMedGoogle Scholar
  7. Greenfeder, S.A., Varnell, T., Powers, G., Lombard-Gillooly, K., Shuster, D., McIntyre, K.W., Ryan, D.E., Levin, W., Madison, V. and Ju, G., 1995, Insertion of a structural domain of interleukin (IL)-1β confers agonist activity to the IL-1 receptor antagonist, J.Biol.Chem., 270: 22460.PubMedCrossRefGoogle Scholar
  8. Hakim, I., Levy, S. and Levy, R., 1996, A nine-amino acid peptide from IL-lβ augments antitumor immune response induced by protein and DNA vaccines. J. Immunol., 157: 5503.PubMedGoogle Scholar
  9. McCune, C.S. and Marquis, D.M., 1990, Interleukin 1 as an adjuvant for active specific immunotherapy in a murine tumor model. Cancer Res., 50: 1212.PubMedGoogle Scholar
  10. Nencioni, L., Villa, L., Tagliabue, A., Antoni, G., Presentini, R., Perin, F., Silvestri, S. and Boraschi, D., 1987, In vivo immunostimulating activity of 163-171 peptide of human IL-1γ, J.Immunol., 139: 800.PubMedGoogle Scholar
  11. Rao, K.V.S. and Nayak, A.R., 1990, Enhanced immunogenicity of a sequence derived from hepatitis B virus surface antigen in a composite peptide that includes the immunostimulatory region from human interleukin 1, Proc.Natl.Acad.Sci. USA, 87: 5519.PubMedCrossRefGoogle Scholar
  12. Tagliabue, A., Ghiara, P. and Boraschi, D., 1992, Non-inflammatory peptide fragments of IL1 as safe new-generation adjuvants, Res.Immunol., 143: 563.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Aldo Tagliabue
    • 1
  • Diana Boraschi
    • 1
  1. 1.Dompé Research CenterL’AquilaItaly

Personalised recommendations